Eli Lilly and Company (NYSE:LLY) Shares Sold by Marietta Investment Partners LLC

Key Points

• Marietta Investment Partners LLC reduced its holdings in Eli Lilly and Company by 10.2%, owning 4,764 shares valued at approximately $3.94 million after selling 540 shares in the first quarter.
• Eli Lilly's latest earnings report showed an EPS of $3.34, missing analysts' expectation of $4.64, despite a revenue increase of 45.2% compared to the same quarter last year.
• The company recently announced a quarterly dividend of $1.50 per share, with a dividend yield of 0.74%, indicating a payout ratio of 48.82%.

Marietta Investment Partners LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,764 shares of the company's stock after selling 540 shares during the quarter. Marietta Investment Partners LLC's holdings in Eli Lilly and Company were worth $3,935,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $43,000. Finally, Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $48,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $811.73 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The business has a 50 day moving average price of $771.95 and a two-hundred day moving average price of $800.41. The firm has a market cap of $769.31 billion, a PE ratio of 66.05, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.58 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. Guggenheim boosted their target price on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.